Abstract:
American Pharmaceutical Partners, Inc.and American BioScience, Inc. (ABI) announced today that theprimary efficacy objective has been exceeded in the randomized, controlled Phase III clinical trial in 460 patients with metastatic breast cancer of ABRAXANE(TM) versus the Cremophor(R) solvent-based TAXOL. Initialanalysis of the data indicates that this solvent-free nanoparticle paclitaxel, ABRAXANE, resulted in higher anti-tumor activity and was not more toxic than TAXOL.